Multiple Myeloma
Featured Articles
(Yahoo! Finance) Feb 7, 2019 - Karyopharm Therapeutics Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the Company’s New Drug Application (NDA) requesting accelerated approval for selinexor, a first-in-class, oral Selective...
Read Article
(PMLiVE [UK]) Feb 5, 2019 - Sanofi’s bid to grab a slice of the multiple myeloma market has advanced thanks to a positive phase 3 trial of isatuximab in relapsed/refractory patients with the blood cancer. Top-line results from the ICARIA-MM trial reveal that the CD38-targeting antibody was able to prolong progression-free survival...
Read Article
Latest Articles
February 12, 2019
February 11, 2019
February 05, 2019
January 29, 2019
January 22, 2019
January 18, 2019
January 11, 2019
January 07, 2019
View More
News Commentary
Editor Image
14 Mar, 2018 | by Thomas Marsland, MD
Drug pricing and the costs of medications is clearly an ongoing problem. But as...
View Comment
Editor Image
07 Mar, 2018 | by Jeff Patton, M.D.
There are certainly some perverse incentives in medicine but there is a...
View Comment
View More
OBR Green
There are no Multiple Myeloma OBR Green articles.
OBR Blog
As the ASH Annual Meeting concludes, the late-breaking abstracts are always of great interest. We take a brief look at... Read more
December 04, 2018